Absci starts Phase 1 dosing for ABS-101; Q1 net loss $26.3M, cash into H1 2027

Absci Corp

2025-Q1 EPS reported -$0.21 revenue$1,179,000

Initiated dosing in first-in-human Phase 1 study of ABS-101 (anti-TL1A); interim data expected H2 2025.
ABS-201 NHP data show extended half-life and >90% subcutaneous bioavailability; Phase 1 start targeted early 2026.
Q1 2025 revenue $1.2M (up from $0.9M YoY); net loss $26.3M vs $22.0M; R&D spending rose to $16.4M.
Cash, equivalents, and short-term investments of $134.0M sufficient to fund operations into first half of 2027.
Company expects to sign one or more new partnerships, including with a large pharma, in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.